China At Global Rare Disease Crossroads: CANbridge CEO
Reimbursement, Regulatory Changes Herald New Era?
The Beijing/Boston-based bioventure shocked the industry with its recent announcement of the return of exclusive rights to an oncology assets in the greater China area to its US licensee, in an effort to focus squarely on rare diseases. CEO James Xue shares his views on this market in China in an exclusive interview with Scrip.
You may also be interested in...
Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while a new biosimilar of a big seller moves into the spotlight.
China's regulators and spin doctors rush to remedy a comment from the nation’s top infectious disease official about the “not high” protection rate for its COVID-19 vaccines, amid debate over speedy development using mature technologies and doubts over protection in seniors. A slow roll-out is already presenting challenges to meeting an official 40% target.
China's historic antitrust fine against Alibaba indicates regulatory attention to anticompetitive practices is mounting. While the pharma sector remains segmented, investigators appear to be taking a generally more sophisticated approach to transgressions.